MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-16-2026
Atara Biotherapeutics Retained Earnings 2011-2026 | ATRA
Retained earnings — this is the portion of a company’s net profit that has not been distributed to shareholders as dividends but remains at the company’s disposal for future use. It is also referred to as retained income or accumulated earnings.Possible uses include
- reinvestment in development (R&D, equipment, marketing)
- debt repayment
- acquisition of other companies
- creation of reserves for the future
A high level of retained earnings indicates that the company is in a growth phase, accumulating capital and prioritizing reinvestment over dividend payouts. Conversely, low or negative retained earnings may suggest either a generous dividend policy, in which all profits are distributed to shareholders, or ongoing losses that reduce the overall financial result.
The presence of retained earnings does not indicate that the company has available cash — it is solely an accounting figure reflecting the accumulated portion of net profit remaining after dividends have been paid. Therefore, it is important for investors to analyze not only the amount of retained earnings, but also how effectively it is used to develop the business, reduce debt, or build financial stability.
Annual Retained Earnings Atara Biotherapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -2.02 B | -2.05 B | -1.97 B | -1.69 B | -1.46 B | -1.12 B | -818 M | -527 M | -297 M | -177 M | -98.1 M | -40.9 M | -12.9 M | -4.11 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -4.11 M | -2.05 B | -879 M |
Quarterly Retained Earnings Atara Biotherapeutics
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -2.02 B | -2.01 B | -2.02 B | -2.05 B | -2.04 B | -2.02 B | -2 B | -1.97 B | -1.91 B | -1.84 B | -1.77 B | -1.69 B | -1.62 B | -1.53 B | -1.55 B | -1.46 B | -1.37 B | -1.29 B | -1.2 B | -1.12 B | -1.12 B | -1.12 B | -1.12 B | -818 M | -818 M | -818 M | -818 M | -527 M | -527 M | -527 M | -527 M | -297 M | -297 M | -297 M | -297 M | -177 M | -177 M | -177 M | -177 M | -98.1 M | -98.1 M | -98.1 M | -98.1 M | -40.9 M | -40.9 M | -40.9 M | -40.9 M | -12.9 M | -12.9 M | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -12.9 M | -2.05 B | -933 M |
Retained Earnings of other stocks in the Biotechnology industry
| Issuer | Retained Earnings | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-158 M | - | 2.43 % | $ 254 M |  Germany |
 |
ARCA biopharma
ABIO
|
-83.7 M | - | 1052.0 % | $ 415 M |  USA |
 |
Processa Pharmaceuticals
PCSA
|
-101 M | $ 2.3 | -1.29 % | $ 3.01 M | USA |
 |
Aeterna Zentaris
AEZS
|
-335 M | - | 5.93 % | $ 314 M |  Canada |
 |
Albireo Pharma
ALBO
|
-301 M | - | -0.23 % | $ 916 M | USA |
 |
Aileron Therapeutics
ALRN
|
-351 M | - | 10.36 % | $ 9.8 M | USA |
 |
I-Mab
IMAB
|
-8.33 B | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
5.24 B | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
-405 M | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
-17.1 M | - | -13.47 % | $ 169 M | France |
 |
Ascendis Pharma A/S
ASND
|
-611 M | $ 220.9 | 2.49 % | $ 5 B |  Danmark |
 |
Aptinyx
APTX
|
-353 M | - | -39.0 % | $ 4.57 M | USA |
 |
Midatech Pharma plc
MTP
|
-122 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-108 M | - | -1.52 % | $ 24.7 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
667 M | $ 19.57 | 1.77 % | $ 915 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-308 M | - | - | $ 26.5 M | USA |
 |
Phathom Pharmaceuticals
PHAT
|
-1.48 B | $ 10.47 | 4.08 % | $ 763 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-149 M | - | - | $ 7.46 M |  Israel |
 |
AgeX Therapeutics
AGE
|
-131 M | - | -10.17 % | $ 12.2 K | USA |
 |
Acorda Therapeutics
ACOR
|
-1.19 B | - | -24.86 % | $ 820 K | USA |
 |
Atreca
BCEL
|
-457 M | - | -11.76 % | $ 5.79 M | USA |
 |
Acasti Pharma
ACST
|
-221 M | - | 4.01 % | $ 150 M | Canada |
 |
BeiGene, Ltd.
BGNE
|
-8.32 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
bluebird bio
BLUE
|
-4.26 B | - | - | $ 546 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
69.4 M | - | - | - |  Russia |
 |
Cara Therapeutics
CARA
|
-685 M | - | -3.03 % | $ 260 M | USA |
 |
Adverum Biotechnologies
ADVM
|
-1.07 B | - | - | $ 86.2 M | USA |
 |
Acer Therapeutics
ACER
|
-141 M | - | 2.71 % | $ 14 M | USA |
 |
Advaxis
ADXS
|
-197 M | - | -9.65 % | $ 45.9 M | USA |
 |
Pliant Therapeutics
PLRX
|
-859 M | $ 1.31 | 2.34 % | $ 80.4 M | USA |
 |
PMV Pharmaceuticals
PMVP
|
-446 M | $ 1.37 | -1.44 % | $ 72 M | USA |
 |
Avenue Therapeutics
ATXI
|
-103 M | - | -52.27 % | $ 4.45 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
-1.1 B | $ 1.33 | 0.76 % | $ 339 M | Britain |
 |
Corbus Pharmaceuticals Holdings
CRBP
|
-555 M | $ 8.31 | 1.59 % | $ 111 M | USA |
 |
CRISPR Therapeutics AG
CRSP
|
-1.95 B | $ 47.09 | 1.42 % | $ 4.23 B |  Schweiz |
 |
Cyclacel Pharmaceuticals
CYCC
|
-439 M | - | -5.98 % | $ 34.1 M | USA |
 |
ChemoCentryx
CCXI
|
-617 M | - | - | $ 3.74 B | USA |
 |
Prelude Therapeutics Incorporated
PRLD
|
-683 M | $ 3.26 | 4.49 % | $ 251 M | USA |
 |
Dynavax Technologies Corporation
DVAX
|
-903 M | - | - | $ 2.02 B | USA |
 |
ProQR Therapeutics N.V.
PRQR
|
-258 M | $ 1.58 | 6.04 % | $ 99.5 M |  Niderland |
 |
BioDelivery Sciences International
BDSI
|
-256 M | - | -4.8 % | $ 255 M | USA |
 |
Enochian Biosciences
ENOB
|
-510 M | - | - | $ 40.5 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-1.13 B | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
-1.06 B | - | - | $ 867 M | Germany |
 |
Palatin Technologies
PTN
|
-459 M | $ 21.0 | 5.79 % | $ 19.5 M | USA |
 |
Bellerophon Therapeutics
BLPH
|
-252 M | - | -74.18 % | $ 955 K | USA |
 |
Akero Therapeutics
AKRO
|
-826 M | - | - | $ 3.67 B | USA |
 |
Pulmatrix
PULM
|
-302 M | $ 2.12 | -1.4 % | $ 7.74 M | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
-1.38 B | $ 4.53 | 5.1 % | $ 868 M | Canada |
 |
Homology Medicines
FIXX
|
-205 M | - | 0.77 % | $ 53.4 M | USA |